US5919619A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Oligonucleotide therapeutic agent and methods of making same
Assignee: Molecular Biosystems Inc
•
Filing: 1995-05-31
•
Granted: 1999-07-06
•
Expires: 2015-05-31
Abstract
Abstract For use in controlling biologic functions in an organism, a stabilized oligonucleotide, preferably in a phosphotriester form, having a base sequence substantially complementary to a portion of messenger ribonucleic acid coding for a bological component, such as a protein, of the organism. The oligonucleotide has about fourteen bases or more, such as twenty-three bases, and can be a deoxyribonucleotide. The oligonucleotide sequence can be derived from the organism's ribonucleic or deoxyribonucleic acid that codes for a vital protein, and can be synthesized in bulk either chemically or by insertion into a plasmid.
Inventors
- 👤 Richard H. Tullis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 00:58
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1131; A; A61; A61K; A61K31/00; A61K31/70; A61K31/7088; A61K31/7135; C07; C07H; C07H21/00; C12N15/1136; C12N2310/00; C12N2310/30; C12N2310/32; C12N2310/321
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
111 words
A method of selectively inhibiting the expression of a target protein in a cell producing messenger ribonucleic acids encoding the target protein and other proteins without inhibiting the expression of the other proteins, with the proviso that the cell is in a cell culture, said method comprising the steps of: (i) synthesizing an oligonucleotide having a base sequence substantially complementary to a subsequence of a messenger ribonucleic acid said subsequence coding for the target protein said oligonucleotide stabilized to inhibit degradation by nucleases; (ii) introducing the oligonucleotide into the cell; and (iii) hybridizing the oligonucleotide to the subsequence of the messenger ribonucleic acid to inhibit the expression of the target protein.
Claim 2
Independent Claim
111 words
A method of selectively inhibiting the expression of a target protein in a cell producing messenger ribonucleic acids encoding the target protein and other proteins without inhibiting the expression of the other proteins, with the proviso that the cell is in a cell culture, said method comprising the steps of: (i) synthesizing an oligonucleotide having a base sequence substantially complementary to a subsequence of a messenger ribonucleic acid said subsequence coding for the target protein said oligonucleotide stabilized to inhibit degradation by nucleases; (ii) introducing the oligonucleotide into the cell; and (iii) hybridizing the oligonucleotide to the subsequence of the messenger ribonucleic acid to inhibit the expression of the target protein.
Claim 3
Dependent Claim
27 words
A method of claim 1 wherein the entire sequence of the oligonucleotide is complementary to the subsequence of a messenger ribonucleic acid coding for the target protein.
Claim 4
Dependent Claim
15 words
A method of claim 1 wherein the oligonucleotide is at least 14 bases in length.
Claim 5
Dependent Claim
14 words
A method of claim 1 wherein the oligonucleotide is about 23 bases in length.
Claim 6
Dependent Claim
16 words
A method of claim 1 wherein the oligonucleotide is between 14 and 23 bases in length.
Claim 7
Dependent Claim
12 words
A method of claim 1 wherein the messenger ribonucleic acid is viral.
Claim 8
Dependent Claim
13 words
A method of claim 1 wherein the messenger ribonucleic acid encodes a hormone.
Claim 9
Dependent Claim
11 words
A method of claim 1 wherein the oligonucleotide is a oligodeoxynucleotide.
Claim 10
Independent Claim
103 words
A method of selectively inhibiting the expression of a target protein in a cell producing messenger ribonucleic acids encoding the target protein and other proteins without inhibiting the expression of the other proteins with the proviso that the cell is in a cell culture, said method comprising the method of: (i) synthesizing an oligonucleotide having a base sequence substantially complementary to a subsequence of a messenger ribonucleic acid said subsequence coding for the target protein; (ii) introducing the oligonucleotide into the cell; and (iii) hybridizing the oligonucleotide to the subsequence of the messenger ribonucleic acid to inhibit the expression of the target protein.
Claim 11
Independent Claim
103 words
A method of selectively inhibiting the expression of a target protein in a cell producing messenger ribonucleic acids encoding the target protein and other proteins without inhibiting the expression of the other proteins with the proviso that the cell is in a cell culture, said method comprising the method of: (i) synthesizing an oligonucleotide having a base sequence substantially complementary to a subsequence of a messenger ribonucleic acid said subsequence coding for the target protein; (ii) introducing the oligonucleotide into the cell; and (iii) hybridizing the oligonucleotide to the subsequence of the messenger ribonucleic acid to inhibit the expression of the target protein.
Claim 12
Independent Claim
78 words
A method of manufacturing an oligonucleotide having a base sequence able to inhibit expression of a protein encoded by an mRNA inside a cell with the proviso that the cell is in a cell culture, said method comprising the steps of: (i) synthesizing an oligonucleotide having a base sequence complementary to the coding region of the mRNA encoding the protein; and (ii) contacting the cell with an amount of oligonucleotide effective to inhibit the expression of the protein.
Claim 13
Independent Claim
78 words
A method of manufacturing an oligonucleotide having a base sequence able to inhibit expression of a protein encoded by an mRNA inside a cell with the proviso that the cell is in a cell culture, said method comprising the steps of: (i) synthesizing an oligonucleotide having a base sequence complementary to the coding region of the mRNA encoding the protein; and (ii) contacting the cell with an amount of oligonucleotide effective to inhibit the expression of the protein.
Claim 14
Dependent Claim
12 words
A method of claim 10 wherein the synthesis is a chemical synthesis.
Claim 15
Dependent Claim
16 words
A method of claim 10 wherein the oligonucleotide is between 14 and 23 bases in size.
Claim 16
Dependent Claim
15 words
A method of claim 10 wherein the oligonucleotide is stabilized to be resistant to degradation.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-07-05 | 2003-01-04 | 2003-07-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-07-05 | 2007-01-04 | 2007-07-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-07-05 | 2011-01-04 | 2011-07-06 | $7700.00 | Window Closed / Lapsed |